ArticleACS omega2020
Fabrication of Decellularized Engineered Extracellular Matrix through Bioreactor-Based Environment for Bone Tissue Engineering.
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Tumor organoid platform design for drug response modeling: culture architecture, microenvironmental complexity, and AI-assisted readouts.Archives of pharmacal research · 2026Review
- A detoxified exosome-ECM hydrogel depot for localized and sustained chemotherapy in prostate cancer.Journal of biological engineering · 2026Article
- Extracellular-Matrix-Based Materials from Decellularized Tissue: Opportunities, Challenges, and Future Directions in Regenerative Medicine.Advanced healthcare materials · 2026Review
- Advances in abiotic tissue-based biomaterials: A focus on decellularization and devitalization techniques.Materials today. Bio · 2025Article
- Decellularized Cell-Secreted Extracellular Matrices as Biomaterials for Tissue Engineering.Small science · 2025Review
- Pre-vascularized porous gelatin-coated β-tricalcium phosphate scaffolds for bone regeneration: an in vivo and in vitro investigation.In vitro cellular & developmental biology. Animal · 2025Article
- Extracellular matrix-derived materials for tissue engineering and regenerative medicine: A journey from isolation to characterization and application.Bioactive materials · 2024Review
- Decellularized extracellular matrix biomaterials for regenerative therapies: Advances, challenges and clinical prospects.Bioactive materials · 2024Review
- Detergent-Based Decellularization for Anisotropic Cardiac-Specific Extracellular Matrix Scaffold Generation.Biomimetics (Basel, Switzerland) · 2023Article
- Decellularization Techniques for Tissue Engineering: Towards Replicating Native Extracellular Matrix Architecture in Liver Regeneration.Journal of functional biomaterials · 2023Review
- 3D Bioprinting for Vascularization.Bioengineering (Basel, Switzerland) · 2023Review
- Recent Methods for Modifying Mechanical Properties of Tissue-Engineered Scaffolds for Clinical Applications.Biomimetics (Basel, Switzerland) · 2023Review
- Cell-scaffold interactions in tissue engineering for oral and craniofacial reconstruction.Bioactive materials · 2023Article
- Advances in hydrogel-based vascularized tissues for tissue repair and drug screening.Bioactive materials · 2022Review
- Bioengineered Living Bone Grafts-A Concise Review on Bioreactors and Production Techniques In Vitro.International journal of molecular sciences · 2022Review
- Perfused Platforms to Mimic Bone Microenvironment at the Macro/Milli/Microscale: Pros and Cons.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular matrix (ECM)-contained grafts can be achieved by decellularization of native bones or synthetic scaffolds. Limitations associated with harvesting the native bone has raised interest in preparing in vitro ECM bioscaffold for bone tissue engineering. Here, we intend to develop an ECM-contained construct via decellularizing an engineered gelatin-coated β-tricalcium phosphate (gTCP) scaffold. In order to find an optimal protocol for decellularization of cell-loaded gTCP scaffolds, they were seeded with buccal fat pad-derived stem cells. Then, four decellularization protocols including sodium dodecyl sulfate, trypsin, Triton X-100, and combined solution methods were compared for the amounts of residual cells and remnant collagen and alteration of scaffold structure. Then, the efficacy of the selected protocol in removing cells from gTCP scaffolds incubated in a rotating and perfusion bioreactor for 24 days was evaluated and compared with static condition using histological analysis. Finally, decellularized scaffolds, reloaded with cells, and their cytotoxicity and osteoinductive capability were evaluated. Complete removal of cells from gTCP scaffolds was achieved from all protocols. However, treatment with Triton X-100 showed significantly higher amount of remnant ECM. Bioreactor-incubated scaffolds possessed greater magnitude of ECM proteins including collagen and glycosaminoglycans. Reseeding the decellularized scaffolds also represented higher osteoinductivity of bioreactor-based scaffolds. Application of Triton X-100 as decellularization protocol and usage of bioreactors are suggested as a suitable technique for designing ECM-contained grafts for bone tissue engineering.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.